These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
296 related articles for article (PubMed ID: 16638934)
1. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Wassmann B; Pfeifer H; Goekbuget N; Beelen DW; Beck J; Stelljes M; Bornhäuser M; Reichle A; Perz J; Haas R; Ganser A; Schmid M; Kanz L; Lenz G; Kaufmann M; Binckebanck A; Brück P; Reutzel R; Gschaidmeier H; Schwartz S; Hoelzer D; Ottmann OG Blood; 2006 Sep; 108(5):1469-77. PubMed ID: 16638934 [TBL] [Abstract][Full Text] [Related]
2. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Pfeifer H; Wassmann B; Pavlova A; Wunderle L; Oldenburg J; Binckebanck A; Lange T; Hochhaus A; Wystub S; Brück P; Hoelzer D; Ottmann OG Blood; 2007 Jul; 110(2):727-34. PubMed ID: 17405907 [TBL] [Abstract][Full Text] [Related]
3. [Imatinib in combination with allogeneic hematopoietic stem cell transplantation improved the outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia]. Cheng Z; Zhao L; Chen G; Wu D; Qiu H; Tang X; Fu C; Jin Z; Chen F; Xue S; Sun A Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):114-9. PubMed ID: 24606651 [TBL] [Abstract][Full Text] [Related]
4. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. de Labarthe A; Rousselot P; Huguet-Rigal F; Delabesse E; Witz F; Maury S; Réa D; Cayuela JM; Vekemans MC; Reman O; Buzyn A; Pigneux A; Escoffre M; Chalandon Y; MacIntyre E; Lhéritier V; Vernant JP; Thomas X; Ifrah N; Dombret H; Blood; 2007 Feb; 109(4):1408-13. PubMed ID: 17062730 [TBL] [Abstract][Full Text] [Related]
5. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Towatari M; Yanada M; Usui N; Takeuchi J; Sugiura I; Takeuchi M; Yagasaki F; Kawai Y; Miyawaki S; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R; Blood; 2004 Dec; 104(12):3507-12. PubMed ID: 15315963 [TBL] [Abstract][Full Text] [Related]
6. [Molecular response and prognostic factors of patients with Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia treated by imatinib with chemotherapy]. Wang J; Huang X; Jiang B; Qin Y; Bao L; Jiang H; Chen H; Jia J; Yang S; Jiang Q Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):120-5. PubMed ID: 24606652 [TBL] [Abstract][Full Text] [Related]
7. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Ottmann OG; Wassmann B; Pfeifer H; Giagounidis A; Stelljes M; Dührsen U; Schmalzing M; Wunderle L; Binckebanck A; Hoelzer D; Cancer; 2007 May; 109(10):2068-76. PubMed ID: 17429836 [TBL] [Abstract][Full Text] [Related]
8. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Ottmann OG; Pfeifer H Hematology Am Soc Hematol Educ Program; 2009; ():371-81. PubMed ID: 20008223 [TBL] [Abstract][Full Text] [Related]
9. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Lee S; Kim YJ; Min CK; Kim HJ; Eom KS; Kim DW; Lee JW; Min WS; Kim CC Blood; 2005 May; 105(9):3449-57. PubMed ID: 15657178 [TBL] [Abstract][Full Text] [Related]
10. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. Yanada M; Takeuchi J; Sugiura I; Akiyama H; Usui N; Yagasaki F; Kobayashi T; Ueda Y; Takeuchi M; Miyawaki S; Maruta A; Emi N; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R; J Clin Oncol; 2006 Jan; 24(3):460-6. PubMed ID: 16344315 [TBL] [Abstract][Full Text] [Related]
11. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Daver N; Thomas D; Ravandi F; Cortes J; Garris R; Jabbour E; Garcia-Manero G; Borthakur G; Kadia T; Rytting M; Konopleva M; Kantarjian H; O'Brien S Haematologica; 2015 May; 100(5):653-61. PubMed ID: 25682595 [TBL] [Abstract][Full Text] [Related]
12. Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571). Scheuring UJ; Pfeifer H; Wassmann B; Bruck P; Atta J; Petershofen EK; Gehrke B; Gschaidmeier H; Hoelzer D; Ottmann OG Blood; 2003 Jan; 101(1):85-90. PubMed ID: 12393581 [TBL] [Abstract][Full Text] [Related]
13. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Chalandon Y; Thomas X; Hayette S; Cayuela JM; Abbal C; Huguet F; Raffoux E; Leguay T; Rousselot P; Lepretre S; Escoffre-Barbe M; Maury S; Berthon C; Tavernier E; Lambert JF; Lafage-Pochitaloff M; Lhéritier V; Chevret S; Ifrah N; Dombret H; Blood; 2015 Jun; 125(24):3711-9. PubMed ID: 25878120 [TBL] [Abstract][Full Text] [Related]
14. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Thomas DA; Faderl S; Cortes J; O'Brien S; Giles FJ; Kornblau SM; Garcia-Manero G; Keating MJ; Andreeff M; Jeha S; Beran M; Verstovsek S; Pierce S; Letvak L; Salvado A; Champlin R; Talpaz M; Kantarjian H Blood; 2004 Jun; 103(12):4396-407. PubMed ID: 14551133 [TBL] [Abstract][Full Text] [Related]
15. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Ribera JM; Oriol A; González M; Vidriales B; Brunet S; Esteve J; Del Potro E; Rivas C; Moreno MJ; Tormo M; Martín-Reina V; Sarrá J; Parody R; de Oteyza JP; Bureo E; Bernal MT; ; Haematologica; 2010 Jan; 95(1):87-95. PubMed ID: 19797728 [TBL] [Abstract][Full Text] [Related]
16. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Spinelli O; Peruta B; Tosi M; Guerini V; Salvi A; Zanotti MC; Oldani E; Grassi A; Intermesoli T; Micò C; Rossi G; Fabris P; Lambertenghi-Deliliers G; Angelucci E; Barbui T; Bassan R; Rambaldi A Haematologica; 2007 May; 92(5):612-8. PubMed ID: 17488684 [TBL] [Abstract][Full Text] [Related]
17. Minimal residual disease-based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia. Lee S; Kim DW; Kim YJ; Chung NG; Kim YL; Hwang JY; Kim CC Blood; 2003 Oct; 102(8):3068-70. PubMed ID: 12842984 [TBL] [Abstract][Full Text] [Related]
18. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. Bassan R; Rossi G; Pogliani EM; Di Bona E; Angelucci E; Cavattoni I; Lambertenghi-Deliliers G; Mannelli F; Levis A; Ciceri F; Mattei D; Borlenghi E; Terruzzi E; Borghero C; Romani C; Spinelli O; Tosi M; Oldani E; Intermesoli T; Rambaldi A J Clin Oncol; 2010 Aug; 28(22):3644-52. PubMed ID: 20606084 [TBL] [Abstract][Full Text] [Related]
19. A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study. Chiaretti S; Vitale A; Vignetti M; Piciocchi A; Fazi P; Elia L; Falini B; Ronco F; Ferrara F; De Fabritiis P; Luppi M; La Nasa G; Tedeschi A; Califano C; Fanin R; Dore F; Mandelli F; Meloni G; Foà R Haematologica; 2016 Dec; 101(12):1544-1552. PubMed ID: 27515250 [TBL] [Abstract][Full Text] [Related]
20. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Ottmann OG; Druker BJ; Sawyers CL; Goldman JM; Reiffers J; Silver RT; Tura S; Fischer T; Deininger MW; Schiffer CA; Baccarani M; Gratwohl A; Hochhaus A; Hoelzer D; Fernandes-Reese S; Gathmann I; Capdeville R; O'Brien SG Blood; 2002 Sep; 100(6):1965-71. PubMed ID: 12200353 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]